LncRNA HAGLROS contribute to papillary thyroid cancer progression by modulating miR-206/HMGA2 expression

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Papillary thyroid cancer (PTC) poses a significant threat to the endocrine system.
• Current treatments for PTC have limited efficacy, necessitating novel therapeutic strategies.
• Investigating molecular interactions offers potential for new treatment avenues.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying PTC progression.
• To identify potential therapeutic targets by studying the HAGLROS/miR-206/HMGA2 interaction.
• To explore novel treatment strategies at the molecular level.

Main Methods:

• Multi-omics analysis to identify differentially expressed RNAs (lncRNA, miRNA, mRNA).
• Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for RNA expression validation.
• Dual-luciferase reporter assays to confirm RNA binding relationships.
• Cellular assays (colony formation, flow cytometry, Transwell) to assess functional impacts.
• In vivo studies using mouse models to evaluate therapeutic effects.

Main Results:

• HAGLROS and HMGA2 were upregulated, while miR-206 was downregulated in PTC tissues and cells.
• HAGLROS and HMGA2 promote PTC cell proliferation and migration while inhibiting apoptosis.
• miR-206 exhibited opposing effects, promoting apoptosis and inhibiting proliferation/migration.
• A negative correlation was observed between HAGLROS/HMGA2 and miR-206 expression.
• Silencing HAGLROS reduced HMGA2 expression and suppressed tumor growth in vivo.

Conclusions:

• HAGLROS promotes PTC growth by competitively binding miR-206, leading to increased HMGA2 expression.
• The HAGLROS/miR-206/HMGA2 axis represents a promising therapeutic target for papillary thyroid cancer.